EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations

Ajaz Bulbul iD, Bridget Noel Fahy, Joanne Xiu, Sadaf Rashad, Asrar Mustafa, Hatim Husain, Andrea Hayes-Jordan

Sarcoma · 2017 · 2017 · 1-12

DOI: 10.1155/2017/1278268 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Sarcoma, 2017. Verfasst von Ajaz Bulbul und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Kymera Independent Physicians, Carlsbad, NM, USA. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Desmoplastic small round blue cell tumors (DSRCTs) originate from a cell with multilineage potential. A molecular hallmark of DSRCT is the EWS-WT1 reciprocal translocation. Ewing sarcoma and DSRCT are treated similarly due to similar oncogene activation pathways, and DSRCT has been represented in very limited numbers in sarcoma studies. Despite aggressive therapy, median survival ranges from 17 to 25 months, and 5-year survival rates remain around 15%, with higher survival reported among those undergoing removal of at least 90% of tumor in the absence of extraperitoneal metastasis. Almost 100% of these tumors contain t(11;22) (p13;q12) translocation, and it is likely that EWS-WT1 functions as a transcription factor possibly through WT1 targets. While there is no standard protocol for this aggressive disease, treatment usually includes the neoadjuvant HD P6 regimen (high-dose cyclophosphamide, doxorubicin, and vincristine (HD-CAV) alternating with ifosfamide and etoposide (IE) chemotherapy combined with aggressively attempted R0 resection). We aimed to review the molecular characteristics of DSRCTs to explore therapeutic opportunities for this extremely rare and aggressive cancer type.

Autor:innen und Institutionen

  • Department of Hematology/Oncology, Kymera Independent Physicians, Carlsbad, NM, USA.
  • Division of Internal Medicine, Department of Hematology/Oncology, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, USA.
  • Department of Surgery, University of New Mexico, Albuquerque, NM, USA.
  • Caris Life Sciences, Phoenix, AZ, USA.
  • All Saints University School of Medicine, Roseau, Dominica.
  • Acharya Shri Chander College of Medical Sciences and Hospital, Jammu, India.

ORCID-Profile: Ajaz Bulbul

Zitieren

APA

Bulbul, A., Fahy, B. N., Xiu, J., Rashad, S., Mustafa, A., Husain, H., & Hayes-Jordan, A. (2017). Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations. Sarcoma, 2017, 1-12. https://doi.org/10.1155/2017/1278268

Vancouver

Bulbul A, Fahy BN, Xiu J, Rashad S, Mustafa A, Husain H, et al. Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations. Sarcoma. 2017;2017:1-12. doi:10.1155/2017/1278268

BibTeX
@article{Bulbul2017,
  author = {Bulbul, Ajaz and Fahy, Bridget Noel and Xiu, Joanne and Rashad, Sadaf and Mustafa, Asrar and Husain, Hatim and Hayes-Jordan, Andrea},
  title = {Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations},
  journal = {Sarcoma},
  year = {2017},
  volume = {2017},
  pages = {1--12},
  doi = {10.1155/2017/1278268}
}
Kostenlos starten →